Article
Oncology
Joshua F. Zeidner, Daniel J. Lee, Mark Frattini, Gil D. Fine, Judy Costas, Kathryn Kolibaba, Stephen P. Anthony, David Bearss, B. Douglas Smith
Summary: Alvocidib, when combined with 7+3 induction therapy, shows promising clinical activity in newly diagnosed acute myeloid leukemia patients, indicating the potential for further investigation of Alvocidib combinations in this population.
CLINICAL CANCER RESEARCH
(2021)
Article
Veterinary Sciences
Shelby L. Mancini, Peter J. Early, Bailey M. Slater, Natasha J. Olby, Christopher L. Mariani, Karen R. Munana, Christian W. Woelfel, Jordan A. Schacher, Li Zhong, Kristen M. Messenger
Summary: This study investigates the feasibility and pharmacokinetics of delivering cytarabine as a subcutaneous continuous-rate infusion using the Omnipod system. The results demonstrate that this method is effective in increasing plasma concentrations of cytarabine and exhibits favorable pharmacokinetic characteristics.
AMERICAN JOURNAL OF VETERINARY RESEARCH
(2022)
Article
Nanoscience & Nanotechnology
Jun Dou, Luoyang Li, Mei Guo, Feng Mei, Danfeng Zheng, Hui Xu, Rui Xue, Xueyang Bao, Fengshu Zhao, Yu Zhang
Summary: The study found that nanozyme-like Fe3O4 nanoparticles (IONPs) combined with cytosine arabinoside (Ara-C) effectively reduced the AML burden in mice engrafted with leukemia stem cells (LSCs) and extended mouse survival by increasing LSC's reactive oxygen species (ROS) levels to induce LSC apoptosis. The results suggest that targeting LSCs with IONPs plus Ara-C could control AML relapse.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Hematology
Mhairi Copland, Cono Ariti, Ian F. Thomas, Laura Upton, Mia Sydenham, Priyanka Mehta, Shahid Islam, Lars Kjeldsen, Alan K. Burnett, Robert K. Hills, Nigel Russell, Mike Dennis
Summary: Improving outcomes for older patients with acute myeloid leukaemia is still an unmet need. In this study, we evaluated the effectiveness of lenalidomide in combination with low-dose cytosine arabinoside compared to low-dose cytosine arabinoside alone in unfit patients aged over 60. The combination therapy showed a higher overall response rate, but there was no difference in overall survival between the two arms.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Irene Graf, Georg Greiner, Rodrig Marculescu, Karoline Gleixner, Susanne Herndlhofer, Gabriele Stefanzl, Paul Knoebl, Ulrich Jaeger, Alexander Hauswirth, Ilse Schwarzinger, Renate Thalhammer, Michael Kundi, Gregor Hoermann, Gerlinde Mitterbauer-Hohendanner, Peter Valent, Wolfgang R. Sperr
Summary: Patient-related factors, including N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, age, and the 2009 European LeukemiaNet (ELN-2009) classification, independently predict outcomes in acute myeloid leukemia (AML) patients receiving induction chemotherapy. Elevated NT-proBNP levels are associated with increased risk of induction failure, early death, and reduced overall survival (OS) in AML patients. These findings highlight the importance of considering cardiac disorders and NT-proBNP as prognostic factors in AML treatment.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Medicine, Research & Experimental
Chao Hu, Xiaofeng Ou, Yi Teng, Shiqing Shu, Ying Wang, Xiaohong Zhu, Yan Kang, Jia Miao
Summary: A study on healthy Chinese subjects showed that continuous infusions of ciprofol demonstrated pharmacodynamic and pharmacokinetic properties similar to propofol, with comparable safety and tolerability.
ADVANCES IN THERAPY
(2021)
Article
Hematology
Tapan M. Kadia, Farhad Ravandi, Matteo Molica, Alex Bataller, Gautam Borthakur, Naval Daver, Elias Jabbour, Courtney D. Dinardo, Naveen Pemmaraju, Nitin Jain, Alessandra Ferrajoli, Musa Ylimaz, Prithviraj Bose, Rebecca Slack Tidwell, Kayleigh R. Marx, Caitlin R. Rausch, Rashmi Kanagal-Shamanna, Sa Wang, Rabiul Islam, Richard Champlin, Elizabeth Shpall, Marina Konopleva, Guillermo Garcia-Manero, Hagop Kantarjian
Summary: The addition of cladribine or sorafenib to standard chemotherapy has improved survival in patients with newly-diagnosed acute myeloid leukemia (AML). The combination of cladribine, idarubicin, and intermediate-dose cytarabine (CLIA) showed high rates of complete remission in AML patients, with even better results when sorafenib was added in patients with FLT3-ITD mutated AML.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Helena Taflin, Elisabeth Odin, Goeran Carlsson, Bengt Gustavsson, Yvonne Wettergren, Elinor Bexe Lindskog
Summary: This pharmacokinetic study compared different dosages and administration regimens of leucovorin (LV) combined with 5-fluorouracil (5-FU) in colorectal cancer patients. The results showed that administering LV as a bolus injection could better potentiate the effect of 5-FU, leading to maximal inhibition of thymidylate synthase (TS), the target enzyme. These findings can help optimize the efficacy of 5-FU.
Article
Veterinary Sciences
Jessica Zilli, Agnieszka Olszewska, Daniela Farke, Martin Juergen Schmidt
Summary: SRMA is an immune-mediated disease typically responsive to corticosteroids. In this case, a mixed breed dog with SRMA received both medical and surgical treatment, highlighting the possibility of successful surgical intervention despite the need for immunosuppressive therapy. D-dimer concentrations were also found to be useful in diagnosing this patient.
ACTA VETERINARIA SCANDINAVICA
(2021)
Article
Gastroenterology & Hepatology
Vinod Arora, Shakti Prasad Choudhary, Rakhi Maiwall, Rajan Vijayaraghavan, Ankur Jindal, Guresh Kumar, Shiv Kumar Sarin
Summary: This study compared the efficacy and adverse events of continuous infusion and bolus administration of terlipressin in cirrhosis patients with acute esophageal variceal bleed. The results showed that continuous infusion led to a higher decline in hepatic venous pressure gradient (HVPG) at a lower dose with fewer adverse events compared to bolus administration within 24 hours.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Critical Care Medicine
Fumitaka Yanase, Thummaporn Naorungroj, Salvatore L. Cutuli, Glenn M. Eastwood, Rinaldo Bellomo
Summary: Results showed that immediate CI response was higher in the rapid fluid bolus therapy group (52%) compared to the combined group (20%). However, at 30 minutes, there was no significant difference in the number of MAP or CI responders between the two groups. Rapid FBT was superior in terms of mean MAP levels and immediate CI response compared to combined FBT.
CRITICAL CARE AND RESUSCITATION
(2021)
Article
Oncology
Yan Huang, Minghua Hong, Zhigang Qu, Weiyan Zheng, Huixian Hu, Linjie Li, Ting Lu, Ying Xie, Shuangwei Ying, Yuanyuan Zhu, Lizhen Liu, Weijia Huang, Shan Fu, Jin Chen, Kangli Wu, Mingsuo Liu, Qiulian Luo, Yajun Wu, Fang He, Jingcheng Zhang, Junyu Zhang, Yu Chen, Minlei Zhao, Zhen Cai, He Huang, Jie Sun
Summary: The study demonstrates that non-ablative chemotherapy followed by HLA-mismatched allo-TLI may be a safe and effective first-line treatment for elderly AML patients and intermediate-2 to high-risk MDS patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Hematology
Courtney D. DiNardo, Sangeetha Venugopal, Curtis Lachowiez, Koichi Takahashi, Sanam Loghavi, Guillermo Montalban-Bravo, Xuemei Wang, Hetty Carraway, Mikkael Sekeres, Ameenah Sukkur, Danielle Hammond, Kelly Chien, Abhishek Maiti, Lucia Masarova, Koji Sasaki, Yesid Alvarado, Tapan Kadia, Nicholas J. Short, Naval Daver, Gautam Borthakur, Farhad Ravandi, Hagop M. Kantarjian, Bhumika Patel, Amy Dezern, Gail Roboz, Guillermo Garcia-Manero
Summary: The combination of enasidenib with azacitidine showed a 74% overall response rate in newly diagnosed mIDH2 MDS patients, while enasidenib monotherapy achieved a 35% response rate in patients after HMA failure. These findings demonstrate that enasidenib is an effective treatment option for mIDH2 MDS.
Letter
Oncology
Amer M. Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, Mikkael A. Sekeres, David P. Steensma, Uwe Platzbecker, Sanam Loghavi, Jacqueline Boultwood, Rafael Bejar, John M. Bennett, Uma Borate, Andrew M. Brunner, Hetty Carraway, Jane E. Churpek, Naval G. Daver, Matteo Della Porta, Amy E. DeZern, Fabio Efficace, Pierre Fenaux, Maria E. Figueroa, Peter Greenberg, Elizabeth A. Griffiths, Stephanie Halene, Robert P. Hasserjian, Christopher S. Hourigan, Nina Kim, Tae Kon Kim, Rami S. Komrokji, Vijay Kutchroo, Alan F. List, Richard F. Little, Ravi Majeti, Aziz Nazha, Stephen D. Nimer, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, David A. Sallman, Guillermo Sanz, Maximilian Stahl, Daniel T. Starczynowski, Justin Taylor, Zhuoer Xie, Mina Xu, Michael R. Savona, Andrew H. Wei, Omar Abdel-Wahab, Valeria Santini
Article
Hematology
Hetty E. Carraway, Daniel A. Pollyea, Eytan M. Stein
Summary: This paper discusses the unresolved challenges and ongoing efforts in the field of acute leukemia and myelodysplasia. While advancements have led to more treatment options, clinicians and researchers are now facing increased challenges and unanswered questions.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
(2022)
Meeting Abstract
Hematology
Waled Bahaj, Tariq Kewan, Carmelo Gurnari, Arda Durmaz, Ben Ponvilawan, Ishani Pandit, Yasuo Kubota, Olisaemeka Ogbue, Mai Aly, Yazan F. Madanat, Taha Bat, Suresh Kumar Balasubramanian, Minako Mori, Manja Meggendorfer, Hetty E. Carraway, Sudipto Mukherjee, Mikkael A. Sekeres, Torsten Haferlach, Valeria Visconte, Jaroslaw P. Maciejewski
Meeting Abstract
Hematology
Zhuoer Xie, Alexandra Smith, Rami S. Komrokji, Najla Al Ali, Anand Ashwin Patel, Caner Saygin, Amer M. Zeidan, Jan Philipp Bewersdorf, Ashwin Kishtagari, Joshua F. Zeidner, Catherine C. Coombs, Yazan F. Madanat, James M. Foran, Talha Badar, Pinkal Desai, Charlton Tsai, Elizabeth A. Griffiths, Monzr M. Al Malki, Idoroenyi Amanam, Catherine Lai, Joachim Deeg, Lionel Ades, Cecilia Arana Yi, Afaf Osman, Shira Dinner, Yasmin Abaza, Namrata Chandhok, Deborah Soong, Justin Taylor, Andrew M. Brunner, Hetty E. Carraway, Abhay Singh Singh, Susan M. Geyer, Eric Padron, Mrinal M. M. Patnaik, Michael R. Savona, Aref Al-Kali
Meeting Abstract
Hematology
Olisaemeka Ogbue, Tariq Kewan, Waled Bahaj, Carmelo Gurnari, Valeria Visconte, Suresh Kumar Balasubramanian, Bhumika J. Patel, Alan Lichtin, Hetty E. Carraway, Jaroslaw P. Maciejewski
Meeting Abstract
Hematology
Jaymeson Gordon, Christopher Haddad, Ishani Nautiyal, Yasuo Kubota, Hetty E. Carraway, Sudipto Mukherjee, Aaron T. Gerds, Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Carmelo Gurnari, Valeria Visconte
Letter
Hematology
Tariq Kewan, Waled Bahaj, Arda Durmaz, Mai Aly, Olisaemeka D. Ogbue, Hetty E. Carraway, Mikkael A. Sekeres, Valeria Visconte, Carmelo Gurnari, Jaroslaw P. Maciejewski
Meeting Abstract
Hematology
Eric Padron, Sara M. Tinsley-Vance, Amy E. DeZern, Hetty E. Carraway, Marlise R. Luskin, Gail J. Roboz, Onyee Chan, Meagan Horton, Aaron T. Gerds, David A. Sallman, Andrew Kuykendall, David Steensma, Maria E. Balasis, Jeffrey E. Lancet, Mikkael A. Sekeres, Rami S. Komrokji
Meeting Abstract
Hematology
Tariq Kewan, Waled Bahaj, Mai Aly, Arda Durmaz, Olisaemeka Ogbue, Hetty E. Carraway, Abhay Singh Singh, Suresh Kumar Balasubramanian, Mikkael A. Sekeres, Valeria Visconte, Carmelo Gurnari, Jaroslaw P. Maciejewski
Meeting Abstract
Hematology
Fauzia Ullah, Danai Dima, Carmelo Gurnari, Suresh Kumar Balasubramanian, Olisaemeka Ogbue, Hussein Awada, Naomi Kawashima, Najiullah Omar, Swapna Thota, Hetty E. Carraway, Valeria Visconte, Jaroslaw P. Maciejewski
Article
Hematology
Amer M. Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, Maximilian Stahl, Lionel Ades, Uma Borate, David Bowen, Rena Buckstein, Andrew Brunner, Hetty E. Carraway, Naval Daver, Maria Diez-Campelo, Theo de Witte, Amy E. DeZern, Fabio Efficace, Guillermo Garcia-Manero, Jacqueline S. Garcia, Ulrich Germing, Aristoteles Giagounidis, Elizabeth A. Griffiths, Robert P. Hasserjian, Eva Hellstrom-Lindberg, Marcelo Iastrebner, Rami Komrokji, Austin G. Kulasekararaj, Luca Malcovati, Yasushi Miyazaki, Olatoyosi Odenike, Valeria Santini, Guillermo Sanz, Phillip Scheinberg, Reinhard Stauder, Arjan A. van de Loosdrecht, Andrew H. Wei, Mikkael A. Sekeres, Pierre Fenaux
Summary: The initial response criteria developed by the International Working Group (IWG) in 2000 have limitations in their application to higher-risk MDS and their ability to fully capture the clinical benefits of novel investigational drugs. Therefore, an international panel of MDS experts used a modified Delphi process to develop consensus recommendations for updated response criteria that would be more reflective of patient-centered and clinically relevant outcomes. The updated criteria should lead to a better correlation between patient-centered outcomes and clinical trial results.
Meeting Abstract
Oncology
Sudipto Mukherjee, Weichuan Dong, Aaron T. Gerds, Hetty E. Carraway, Abhay Singh, Anjali S. Advani, Siran M. Koroukian
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2023)
Meeting Abstract
Oncology
Farhad Ravandi-Kashani, Ashwin Kishtagari, Hetty Carraway, Emily Curran, Gary Schiller, Alex Cacovean, Bhagyashree Yadav, Thomas Butler, Jeffrey Lancet
Meeting Abstract
Oncology
Farhad Ravandi, Hetty Carraway, Jack Khouri, Ashwin Kishtagari, Emily Curran, Gary Schiller, Bhagyashree (Kelshikar) Yadav, Steve Morris, Alex Cacovean, Sanchita Mourya, Thomas Butler, Jeffrey Lancet
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)